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Sleeping sickness, also known as human
African trypanosomiasis (HAT), is one of
the neglected tropical diseases of sub-
Saharan Africa that has plagued human
health and agricultural development. In
West Africa, infection with Trypanosoma
brucei gambiense gives rise to a chronic
disease that mainly affects humans. Infec-
tion with T. b. gambiense accounts for more
than 90% of reported sleeping sickness
cases. In East Africa, infection with
Trypanosoma brucei rhodesiense generates
acute disease in humans, and also circu-
lates in a relatively unaffected livestock
reservoir. Both Gambian and Rhodesian
sleeping sickness are fatal if left untreated.
The parasites are transmitted to the
mammalian host through the bite of an
infected tsetse fly.
Since its discovery a century ago,
several waves of HAT epidemics have
plagued the continent. During the colonial
regimes, it was possible to bring about a
steady decline in the number of reported
gambiense cases from the 1930s onwards
with systematic screening, treatment, and
patient follow-up in western and central
Africa. However, during the post-indepen-
dence period of the 1960s when HAT
cases declined, control programs within
the endemic countries gradually were run
down, resulting in a steep rise in incidence
during the following 40 years. It has been
difficult to estimate the true burden of
HAT, as the disease affects the most
neglected populations living in remote
and rural settings where the majority of
people affected are beyond the reach of
health care systems and are not reported
in any of the health metrics [1]. The
World Health Organization (WHO) Ex-
pert Committee on HAT control and
surveillance estimated in 1995 that the
true number of cases was at least 10 times
more than that reported considering the
huge uncertainties between the reported
cases and the factual field situation. Thus,
from the 30,000 reported cases annually, it
was estimated that some 300,000 infected
individuals remained infected in the field
[2].
In this issue of PLoS Neglected Tropical
Diseases, Pere P. Simarro and colleagues
from WHO report that the number of
new cases diagnosed with HAT in 2009
has dropped below 10,000 for the first
time in 50 years, signaling a possible end
to the latest epidemic cycle as a major
public health problem. This decline was
achieved through an ambitious campaign
led by WHO, and many nongovernmen-
tal organizations (NGOs) and thanks to
a public–private partnership with Sanofi-
Aventis and Bayer to donate and distrib-
ute the necessary drugs to WHO for use
in affected countries. Without this gener-
osity, patients would have no access to
life-saving drugs, however unsatisfactory,
given that many national health budgets
are already stretched. A new nifurtimox/
eflornithine combination treatment (NECT)
was also developed recently that reduced
both the cost of drugs and their delivery
[3,4]. Also crucial in HAT control was
the recognition of the problem by African
heads of state and governments during the
African Union Summit in Lome ´i n2 0 0 0
where the Pan African Tsetse and Trypano-
somiasis Eradication Campaign (PATTEC)
was initiated with the objective to render
Africa a tsetse- and trypanosomiasis-free
continent [5]. While the news of reaching
a probable elimination phase for HAT is
most welcoming, sustainable management
of disease control now poses a formidable
challenge to endemic countries and health
ministries that have to juggle a multitude of
diseases when faced with shortages of funds.
If the decline in the reported HAT cases is
taken at face value, it could signal African
governments to abandon their local control
efforts and for funding agencies to modify
their disease research priorities. Should this
happen, it is most certain that epidemics will
likely flare up in the near future as has
happened in the past.
Given that HAT epidemiology varies
significantly for rhodesiense and gambiense
disease, the measures adopted will have to
vary in different epidemiological settings.
Nevertheless, since the distribution of
sleeping sickness is limited to ancient and
in many cases well-recognized foci, vigi-
lant monitoring through surveillance at
these foci should be continued for both
forms of the disease. Towards this end, in
February 2008 WHO launched the initia-
tive of the Atlas of HAT to map all
reported cases for the period 2000–2009 at
the village level, which should be contin-
ued and updated [6]. Many reports have
highlighted the feared merger of the
gambiense and rhodesiense disease belts in
Uganda, which would cause havoc given
the different diagnostics and treatment
regiments required for two diseases. Con-
tinued monitoring of diseases emerging in
the potential merger zone has to remain a
high priority for Uganda. For the rhode-
siense disease with documented animal
reservoirs, stringent implementation of
animal treatments at livestock markets
should continue to be a priority, especially
in Uganda where cattle movements have
been suggested to result in the continued
spread of rhodesiense disease into new
territories [7].
Despite intensive research into the
biology of the trypanosomes and tsetse,
to date the toolbox for diagnostics and
treatment of sleeping sickness has re-
mained extremely small and plagued with
difficulties [8]. This is largely due to the
complexity of the parasite’s biology where
an antigenic variation mechanism has
hampered the development of mammalian
vaccines. There are no prophylactic drugs.
Furthermore, clinical tests applicable in
the field for staging of disease have been
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knowledge accumulated on parasite and
tsetse biology and the unprecedented tech-
nological advancements we are witnessing
in science at this time provide the impetus
for continued future research where the
prospects for translational science are
excellent. You can find a sample of the
research that has been published in PLoS
Neglected Tropical Diseases highlighting such
promising discoveries in the special collec-
tion presented in this issue. It is most likely
that innovative and interdisciplinary cut-
ting-edge research will lead the way for
improved and effective toolstomonitorand
prevent the next epidemic.
One promising area is in the develop-
ment of DNA-based diagnostic tools such
as the use of the loop-mediated isothermal
amplification (LAMP) method for rapid
detection of parasites in the field setting
[9,10]. This approach can also be applied
to detect the circulating infectious para-
sites in natural tsetse populations or in
reservoir animals to monitor the potential
risk for human disease emergence during
endemic periods. It has also been suggest-
ed that piggybacking HAT diagnostic
efforts on the platforms already used for
other diseases, such as tuberculosis as well
as malaria and HIV, can lead to more
sustainable surveillance efforts [11]. One
immediate application is the use of a light-
emitting diode (LED)–based fluorescence
microscope developed for tuberculosis,
which has been found to be highly sensitive
for trypanosome diagnostics. Use of mini
anion exchange centrifugation technique
(mAECT) has improved diagnosis of T. b.
gambienseinfections,whicharehardtodetect
due to low parasite densities in patient
blood [12]. Continued research into safe,
effective, and easy-to-use treatments are
essential such as the recently rediscovered
compound fexinidazole, which has entered
into clinical development for the treatment
of sleeping sickness [13].
A most effective means of preventing
disease transmission is to remove tsetse
flies, either at a local level (e.g., a group of
villages) or regionally (covering large parts
of a country or region). However, a major
problem has been the cost and logistical
difficulty of implementing such control
programs. New research into variations of
target design now indicate that catch
efficiencies of the major human disease
vector species Glossina fuscipes fuscipes can
be improved by at least 10-fold, resulting
in a considerable (more than 6-fold) cost
saving for control programs [14]. Tsetse
population genetics information has re-
peatedly identified extensive structuring in
the field [15,16]. Closer communication
between the scientific community and
vector control programs should be en-
couraged, as vector genetics information
can benefit the ongoing control activities
in the field and improve the sustainability
of tsetse reduction efforts [17]. Eco-
epidemiology is another growing discipline
that can benefit HAT control efforts
through the identification of potential
disease loci and tsetse breeding sites for
targeted control efforts as well as any
potential impact of the anticipated climate
change on disease patterns.
Finally, the genomes of the human host
and the infectious trypanosomes have been
sequenced [18]. Technological advance-
ments have made it possible to determine
the transcriptome of the trypanosome
parasite at a single nucleotide level [19],
opening up prospects for future studies
where discoveries into disease stage–specific
transcriptomes or proteomes will surely
identify novel molecules for diagnostics
and therapies. An international consortium
of scientists brought together by WHO/
TDR hasrecently announced that the tsetse
vector genome (Glossina morsitans morsitans)i s
in the final stages of annotation [20,21].
Furthermore, the United States National
Institutes of Health has recently approved a
comprehensive project to obtain the ge-
nome sequence of five additional tsetse
species along with extensive transcriptome
analysis. An immediate application of
genomics discoveries could be on vector
olfactory biology and could speed up
investigations for the development of spe-
cies-specific and cost-effective chemicals
such as attractants to lure tsetse to targets
and traps to reduce population densities
[22,23]. Lack of such chemicals for human
disease–transmitting tsetse species has dis-
couraged extensive use of vector control.
Tsetse–trypanosome interactions can also
now be investigated at the molecular level,
and this has the potential to lead to
pathways or targets to block the parasite’s
transmission ability in the vector.
In conclusion, it is time to celebrate the
efforts of the HAT community that has
succeeded in curbing the latest epidemic.
However, it is important to remember that
there are still 10,000 cases out there that
need our attention. It is also important to
remember that countries must put in place
mechanisms and health personnel who
can recognize and report any potential
HAT cases in endemic areas to prevent
the reemergence of disease. Finally, this is
not the time to abandon research on tsetse
and trypanosomes, but rather to exploit
the accumulating knowledge in light of the
technological advancements and build the
toolbox by moving discoveries from bench
to field for more effective diagnostics,
therapies, and vector control methods.
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